HONG KONG, November 9, 2022 /PRNewswire/ — On November 8, 2022we received good news from the 5th China International Import Expo (CIIE): the 1st in Shanghai, for the world announced the recipients of the IPs SHANGHAI Business Case Best Practice Award in Global Communication. The Organizing Committee awarded Fosun International the IP SHANGHAI Global Communications Corporate Case Best Practice Award, in recognition of Fosun International’s outstanding practices in global public health, including malaria and epidemic control efforts.
This is China first large-scale corporate event in the field of global communications on the theme of urban intellectual property. The event was organized by IPs SHANGHAI and the Shanghai International Studies University Global Communication Case Management Platform and was supported by the Shanghai Daily Multinational Companies Club.
As a company rooted in Shanghai, China, Fosun has always been dedicated to public health with its innovative products and global resources. Over the years, he has been involved in anti-malaria campaigns in China and around the world, and has organized a series of public welfare activities with its global member societies to raise awareness of the importance of malaria prevention and control around the world.
Artesuante self-developed and manufactured for injection to build a malaria-free world
According to the World Health Organization (WHO), in 2020 there were approximately 241 million cases of malaria worldwide and 627,000 malaria-related deaths worldwide. Of which, 95% of cases and 96% of deaths related to malaria occurred in Africaabout 80% of whom are children under the age of five.
In the 1970s, a Chinese scientist You you you first developed a new technology to extract artemisinin from ether. Based on this technology, a series of new antimalarial drugs including Chinese artesunate No. X-01 have been developed, which have innovatively advanced the fight against malaria.
On December 21, 2005, artesunate tablet innovated by Fosun Pharma has become the first WHO-prequalified pharmaceutical product (WHO-PQ), representing a breakthrough for the Chinese pharmaceutical industry. In 2011, Artesun®, artesunate for injection, self-developed and manufactured by Fosun Pharma, was recommended by the WHO as first-line treatment for severe malaria. By the end of 2021, it had been used to treat more than 48 million patients with severe malaria worldwide.
Fosun works tirelessly to support the global fight against malaria. In April 2021, the Fosun Foundation has actively responded to the “Zero Malaria Starts with Me” campaign initiated by the WHO and the “Roll Back Malaria Partnership”. Slogans, “Zero Malaria Starts with Me” and “Together We Build a Malaria-free World”, were displayed on advertising screens in Fosun’s landmark buildings, including the Bund Finance Center in Shanghai28 Freedom in New YorkEN Hotel Kyoto and EN Hotel Hiroshima in JapanAtlantis Sanya, the Bund Fosun Center in Wuhan.
English Premier League players Wolverhampton Wanderers FC have made a video to call on everyone to take malaria prevention and control measures seriously and stress that malaria prevention and control is as important as taking good precautionary measures against COVID-19. The Fosun Foundation and Fosun Pharma organized the “Drawing a World Without Malaria” drawing competition at the Beacon International School in Ghana raise children’s awareness of malaria prevention and environmental protection. Fosun conducted a series of public welfare activities to call on the public to work together to fight malaria.
Use of Chinese antimalarial drugs in Africa to help more people
In order to achieve the ultimate goal of building a malaria-free world, Fosuner, Cyrus Baidoowent to the front line Africawhere malaria is most severe, and has helped and cured many malaria patients with Chinese antimalarial medicine.
Cyrus Baidoo is the Marketing Director of Fosun Pharma Sub-Saharan Africa. He visits many local hospitals every day to promote Chinese antimalarial medicines to doctors and patients. Many years ago, Cyrus worked in a world famous pharmaceutical company before joining Fosun. “A lot of my friends didn’t understand why I left an American company for a Chinese company. They said the company was too new and had hardly any products,” Cyrus recalls.
From being misunderstood and distrustful of Chinese companies to now, where Fosun Pharma has become a global leader in malaria drugs and one of the most influential Chinese pharmaceutical brands in Africa, Cyrus has witnessed the rapid development of Fosun Pharma in the field of antimalarial drugs. From January 2022Guilin Pharma, a subsidiary of Fosun Pharma, has a total of 30 WHO-prequalified (WHO-PQ) antimalarial products, including 26 finished dosage forms and four APIs, making Fosun Pharma the leading antimalarial drug manufacturer with the most certificates.
In August 2018, Fosun Pharma’s SPAQ-CO® Disp (sulfadoxine-pyrimethamine dispersible tablets and amodiaquine dispersible tablets), indicated for the prevention of malaria in children, has been prequalified by the WHO (WHO-PQ). By the end of 2021, approximately 175 million children in African countries with high malaria transmission had benefited from the “Seasonal Malaria Chemoprevention Program”, for which SPAQ-CO® Disp is used as the basic drug to effectively reduce malaria morbidity in children under five years of age Africa.
Guo Guangchang, Chairman of Fosun International, said, “As a partner in the fight against malaria for China and around the world, Fosun is constantly committed to providing more advanced solutions such as innovative medicines and global resources for malaria management and control. We will join forces and resources and work with malaria scientists as well as health professionals to continue to carry out malaria education projects for the public, to capitalize on people’s awareness of the disease. malaria prevention. We will actively participate in improving public health and make constant efforts to build a world without malaria. »
In Shanghai, For the world. Thirty years after its establishment, Fosun will continue to uphold the original aspiration of “self-improvement, teamwork, performance and contribution to society”, will devote itself to global public health and welfare enterprises. be public, and will provide innovative products and services to create happier lives for families around the world.